ADAP: Adaptimmune Therapeutics plc Net earnings per share (EPS TTM)

Public company logo of Adaptimmune Therapeutics plc (ADAP)

The rolling earnings per share trend demonstrates the impact of the innovative Tecelra launch on financial performance, with the latest reading standing at -0.65. Adaptimmune's authority in treating solid tumors strengthens market confidence, although high drug launch costs and competition in oncology create risks. Investors see real cost pressure through the EPS dynamics.

ADAP (Adaptimmune) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/15/2025

Adaptimmune Therapeutics plc - analytical breakdowns and key metrics (ADAP)

- share price and expert price forecast:
Stock Quotes Adaptimmune Therapeutics PLC|ADAP - Fair Value Consensus
- market capitalization information:
Market Capitalization Adaptimmune Therapeutics plc|ADAP - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share Adaptimmune Therapeutics|ADAP - Total Stockholders' Equity|Market Value to Book Value Ratio adaptimmune.com|ADAP - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Adaptimmune|ADAP - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Adaptimmune Therapeutics PLC|ADAP - Aggregate Debt Obligations|Debts to Book Capitalization Adaptimmune Therapeutics plc|ADAP - Long-Term Indebtedness|Company Short-Term Debts Adaptimmune Therapeutics|Quick Liquidity adaptimmune.com
- net income and valuation multiples indicators:
ADAP - Company Profit|Projected Future Earnings Adaptimmune|ADAP - Market Cap to Earnings|Projected Price to Earnings Adaptimmune Therapeutics PLC|ADAP - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Adaptimmune Therapeutics plc|ADAP - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Adaptimmune Therapeutics|ADAP - Earnings per share for the trailing year|Quarterly EPS earnings growth adaptimmune.com|ADAP - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Adaptimmune
General company analysis:adaptimmune.com (ADAP)
Mass-produced product of Adaptimmune

This indicator is calculated as the ratio of total net income to the total number of shares outstanding. It determines the portion of profit attributable to a single security over the last twelve months. Outsourcing clinical trials to external contractors helps Adaptimmune (ADAP) optimize R&D expenses, directly impacting final profitability. By analyzing the company's rolling annual earnings per share, an investor assesses the efficiency of capital management. The trend of this line signals the degree of stability in the business's margins.

Analysis of competing companies

LEGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year SANA (sana.com)|AUTL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Allogene Therapeutics, Inc.|RNAC (Cartesian Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cellectis Biotherapeutics CLLS|Earnings per share for the last twelve months Caribou Biosciences (CRBU)|Earnings per share for the last twelve months TIL (instilbio.com)|Earnings per share for the last twelve months Genenta Science GNTA|Century Tx - Earnings per share for the last twelve months|JSPR: Net earnings per share for the last 12 months|Earnings per share for the trailing year SNTI (Senti Biosciences, Inc.)|CERO: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Alaunos Therapeutics, Inc. TCRT|ACHL (Achilles Therapeutics PLC) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CARGO Therapeutics Inc. CRGX|Earnings per share for the last twelve months Poseida (PSTX)|2seventy bio, Inc - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRCL (Gracell Biotechnologies)